Vor Biopharma Inc. (VOR)
USD 0.89
(-8.84%)
USD 0.89
(-8.84%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -100.29 Million | -85.14 Million | -69.14 Million | -36.29 Million | -9.85 Million | -2.66 Million |
| Net Income | -117.86 Million | -92.09 Million | -68.89 Million | -43.33 Million | -10.83 Million | -4.15 Million |
| Depreciation & Amortization | 3.49 Million | 2.52 Million | 1.43 Million | 605 Thousand | 91 Thousand | 20 Thousand |
| Deferred income taxes | -2.85 Million | - | - | - | -32 Thousand | 289 Thousand |
| Stock-based compensation | 13.36 Million | 10.69 Million | 4.31 Million | 1.34 Million | 172 Thousand | 116 Thousand |
| Change in working capital | 650 Thousand | -12.69 Million | -9.18 Million | 4.31 Million | 145 Thousand | 63 Thousand |
| Other non-cash items | 2.91 Million | 6.42 Million | 3.19 Million | 782 Thousand | 608 Thousand | 1 Million |
| Investing Cash Flow | 71 Million | -94.09 Million | -91.65 Million | -4.16 Million | -748 Thousand | - |
| Investments in PPE | -1.06 Million | -8.46 Million | -3.89 Million | -4.16 Million | -748 Thousand | - |
| Acquisitions | -72.07 Thousand | - | - | - | - | - |
| Investment purchases | -74.92 Million | -123.18 Million | -87.75 Million | - | - | - |
| Sales/Maturities of investments | 147 Million | 37.56 Million | - | - | - | - |
| Other Investing Activities | 72.07 Thousand | - | -87.75 Thousand | - | - | - |
| Financing Cash Flow | 2.93 Million | 117.14 Million | 232.91 Million | 82.52 Million | 17.69 Million | 2.46 Million |
| Debt repayment | - | - | - | - | - | -2.46 Million |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | -1.18 Million | - | - | - | - | - |
| Common Stock Issuance | 4.12 Million | 115.97 Million | 232.91 Million | 82.26 Million | 17.69 Million | - |
| Other Financing Activities | -1.18 Million | 1.16 Million | 232.91 Million | 259 Thousand | 17.69 Thousand | 2.46 Million |
| Accounts receivables | - | - | - | - | - | - |
| Accounts payables | 2.85 Million | 0.81 | 405 Thousand | 5.82 Million | 1.21 Million | 65 Thousand |
| Inventory | - | - | - | - | - | - |
| Other working capital | -2.2 Million | -12.69 Million | -9.59 Million | -1.5 Million | -1.06 Million | 63 Thousand |
| Cash at beginning of period | 57.7 Million | 122.21 Million | 50.09 Million | 8.02 Million | 929 Thousand | 1.12 Million |
| Cash at end of period | 31.36 Million | 60.11 Million | 122.21 Million | 50.09 Million | 8.02 Million | 929 Thousand |
| Capital Expenditure | -1.06 Million | -8.46 Million | -3.89 Million | -4.16 Million | -748 Thousand | - |
| Effect of forex changes on cash | - | - | - | - | - | - |
| Net cash flow / Change in cash | -26.34 Million | -62.09 Million | 72.11 Million | 42.07 Million | 7.09 Million | -197 Thousand |
| Free Cash Flow | -101.36 Million | -93.6 Million | -73.03 Million | -40.45 Million | -10.6 Million | -2.66 Million |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -27.83 Million | -30.8 Million | -117.86 Million | -26.26 Million | -33.19 Million | -29.97 Million |
| Depreciation & Amortization | 900 Thousand | 943 Thousand | 3.49 Million | 892 Thousand | -1.42 Million | 3.18 Million |
| Deferred income taxes | - | - | -2.85 Million | -3.5 Million | 5.44 Million | 1.04 Million |
| Stock-based compensation | 2.79 Million | 3.08 Million | 13.36 Million | 1.89 Million | 3.16 Million | 4.23 Million |
| Change in working capital | 1.4 Million | -4.12 Million | 650 Thousand | -779 Thousand | 1.26 Million | 1.65 Million |
| Other non-cash items | 4.93 Million | 7.88 Million | 2.91 Million | 3.73 Million | -3.16 Million | -4.23 Million |
| Investing Cash Flow | 52.99 Million | 43.97 Million | 71 Million | 10.33 Million | 40.53 Million | 13.63 Million |
| Investments in PPE | -9000.00 | -114 Thousand | -1.06 Million | -111 Thousand | -465 Thousand | -399 Thousand |
| Acquisitions | - | - | -72.07 Thousand | 61.63 Thousand | -41 Thousand | -14.03 Thousand |
| Investment purchases | -1000.00 | -9.91 Million | -74.92 Million | -16.55 Million | 1000.00 | -34.96 Million |
| Sales/Maturities of investments | 53 Million | 54 Million | 147 Million | 27 Million | 41 Million | 49 Million |
| Other Investing Activities | - | 44.08 Million | 72.07 Thousand | -1.00 | 41 Thousand | 14.03 Thousand |
| Financing Cash Flow | -31 Thousand | 96 Thousand | 2.93 Million | 25 Thousand | 176 Thousand | 218 Thousand |
| Debt repayment | - | - | - | - | - | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | -182 Thousand | -1.18 Million | -22.00 | -220.00 | -545.00 |
| Common Stock Issuance | 20 Thousand | 278 Thousand | 4.12 Million | 47 Thousand | 392 Thousand | 579 Thousand |
| Other Financing Activities | -51 Thousand | -182 Thousand | -1.18 Million | -22 Thousand | -215.78 Thousand | -360.45 Thousand |
| Accounts receivables | - | - | - | - | - | - |
| Accounts payables | 551 Thousand | -2.48 Million | 2.85 Million | 172 Thousand | 2.65 Million | 107 Thousand |
| Inventory | - | - | - | - | - | - |
| Other working capital | 857 Thousand | -1.63 Million | -2.2 Million | -951 Thousand | -1.39 Million | 1.54 Million |
| Cash at beginning of period | 44.96 Million | 31.36 Million | 57.7 Million | 45.02 Million | 34.62 Million | 42.45 Million |
| Cash at end of period | 76.07 Million | 44.96 Million | 31.36 Million | 31.36 Million | 47.43 Million | 4.23 Million |
| Capital Expenditure | -9000.00 | -114 Thousand | -1.06 Million | -111 Thousand | -465 Thousand | -399 Thousand |
| Effect of forex changes on cash | - | - | - | -4.82 Million | -9.65 Million | 14.48 Million |
| Net cash flow / Change in cash | 31.11 Million | 13.6 Million | -26.34 Million | -13.66 Million | 12.81 Million | -38.21 Million |
| Free Cash Flow | -21.85 Million | -30.57 Million | -101.36 Million | -24.13 Million | -28.36 Million | -24.49 Million |
080160
LIPI
9521
8010
ATS
JBMA